MET and non-small cell lung carcinoma: Tepotinib is currently approved for treating advanced or metastatic METex14 skipping NSCLC in many countries in Europe, North America, South America, and Asia, including Hong Kong, Japan, Singapore, South Korea, Taiwan, India, and Macao, and is the first MET inhibitor with full approval in China.